The classic website will no longer be available as of June 25, 2024. Please use the modernized ClinicalTrials.gov.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Long-term Study of Nemolizumab (CD14152) in Participants With Prurigo Nodularis (PN)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04204616
Recruitment Status : Active, not recruiting
First Posted : December 19, 2019
Last Update Posted : October 11, 2023
Sponsor:
Information provided by (Responsible Party):
Galderma R&D

Study Description
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
The primary purpose of this study is to assess the long-term safety of nemolizumab (CD14152) in participants with prurigo nodularis (PN).

Condition or disease Intervention/treatment Phase
Prurigo Nodularis Drug: Nemolizumab Phase 3

Study Design
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 450 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Prospective, Multicenter, Long-Term Study to Assess the Safety and Efficacy of Nemolizumab (CD14152) in Subjects With Prurigo Nodularis
Actual Study Start Date : January 11, 2021
Estimated Primary Completion Date : October 26, 2026
Estimated Study Completion Date : October 26, 2026

Resource links provided by the National Library of Medicine


Arms and Interventions
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm Intervention/treatment
Experimental: Nemolizumab
Participants weighing less than (<) 90kilogram (kg) will receive 30 milligram (mg) nemolizumab every 4 weeks (Q4W) and participants weighing greater than or equal to (>=) 90 kg will receive 60 mg nemolizumab (two 30-mg injections) Q4W.
 Drug: Nemolizumab
Nemolizumab 30 mg will be administered as subcutaneous (SC) injection.
Other Name: CD14152


Outcome Measures
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. Incidence of Adverse Events (AEs) by Severity [ Time Frame: Up to 192 weeks ]
    Incidence of AEs including AEs of Special Interest (AESIs), Treatment Emergent AEs (TEAEs) and Serious AEs (SAEs) by severity as mild, moderate or severe will be reported. An AE is any untoward medical event that occurs in a participant administered an investigational product, and it does not necessarily indicate only events with clear causal relationship with relevant investigational product. SAE is any untoward medical occurrence that at any dose may results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, is a suspected transmission of any infectious agent via a medicinal product. TEAE is an AE that occurs on or after the first date of study drug(s) administration until the date of last study visit. An AESI is a noteworthy treatment-emergent event for the study drug that should be monitored closely and reported promptly.


Secondary Outcome Measures :
  1. Percentage of Participants with an Investigator Global Assessment (IGA) Success up to Week 184 [ Time Frame: Up to Week 184 ]
    Percentage of participants with an IGA success (defined as IGA of 0 [Clear] or 1 [Almost clear]) up to Week 184 will be reported.

  2. Percentage of Participants with an Improvement of >=4 from Baseline in Peak Pruritus (PP) Numeric Rating Scale (NRS) up to Week 184 [ Time Frame: Baseline up to Week 184 ]
    Percentage of participants with an improvement of >= 4 from baseline in PP NRS up to Week 184 will be reported. The PP NRS has a scale of 0 to 10, with 0 being "no itch" and 10 being "worst itch imaginable".

  3. Percentage of Participants with Low Disease Activity State up to Week 184 [ Time Frame: Up to Week 184 ]
    Percentage of participants with low disease activity state (that is, IGA <=2) up to Week 184 will be reported.

  4. Percentage of Pruriginous Lesions with Excoriations/Crusts up (PAS item 5a) up to Week 184 [ Time Frame: Up to Week 184 ]
    PAS will include a count of the number of lesions in a representative area and a calculated staging (stage 0 to stage 4) based on the percentage of lesions with excoriations/crusts and healed lesions compared to all lesions. PAS item 5a reflects the current itch/scratch activity. It is used to estimate what percentage of the pruriginous legions show excoriations/crusts. 100 percent (%) = All pruriginous lesions have excoriations/crusts. Percentage of pruriginous lesions with excoriations/crusts (PAS item 5a) up to Week 184 will be reported.

  5. Percentage of Healed Prurigo Lesions (PAS item 5b) up to Week 184 [ Time Frame: Up to Week 184 ]
    PAS item 5b item reflects the stage of the prurigo. It is used to estimate what percentage of the pruriginous lesions have healed.100% = all pruriginous lesions have healed. Percentage of healed prurigo lesions (PAS item 5b) up to Week 184 will be reported.

  6. Change from Baseline in Number of Lesions in Representative Area (PAS item 4) up to Week 184 [ Time Frame: Baseline up to Week 184 ]
    Change from baseline in number of lesions in representative area (PAS item 4) up to Week 184 will be reported.

  7. Percentage of Participants with PP NRS <2 up to Week 184 [ Time Frame: Up to Week 184 ]
    Percentage of participants with PP NRS <2 up to Week 184 will be reported. PP NRS is a scale of 0 to 10, with 0 being "no itch" and 10 being "worst itch imaginable".

  8. Percent Change from Baseline in PP NRS up to Week 184 [ Time Frame: Baseline up to Week 184 ]
    Percent change from baseline in PP NRS up to Week 184 will be reported. PP NRS is a scale of 0 to 10, with 0 being "no itch" and 10 being "worst itch imaginable".

  9. Absolute Change from Baseline in PP NRS up to Week 184 [ Time Frame: Baseline up to Week 184 ]
    Absolute change from baseline in PP NRS up to Week 184 will be reported. PP NRS is a scale of 0 to 10, with 0 being "no itch" and 10 being "worst itch imaginable".

  10. Percentage of Participants with Average Pruritus (AP) NRS <2 up to Week 52 [ Time Frame: Up to Week 52 ]
    Percentage of participants with AP NRS less than (<) 2 up to Week 52 will be reported. AP NRS has a scale of 0 to 10, with 0 being "no itch" and 10 being "worst itch imaginable".

  11. Percentage of Participants with an Improvement of >=4 from Baseline in AP NRS up to Week 52 [ Time Frame: Up to Week 52 ]
    Percentage of participants with an improvement of >=4 from baseline in AP NRS up to Week 52 will be reported. AP NRS has a scale of 0 to 10, with 0 being "no itch" and 10 being "worst itch imaginable".

  12. Percent Change from Baseline in AP NRS up to Week 52 [ Time Frame: Up to Week 52 ]
    Percent change from baseline in AP NRS up to Week 52 will be reported. AP NRS has a scale of 0 to 10, with 0 being "no itch" and 10 being "worst itch imaginable".

  13. Absolute Change from Baseline in AP NRS up to Week 52 [ Time Frame: Up to Week 52 ]
    Absolute change from baseline in AP NRS up to Week 52 will be reported. AP NRS has a scale of 0 to 10, with 0 being "no itch" and 10 being "worst itch imaginable".

  14. Percentage of Participants with an Improvement of >=4 from Baseline in Sleep Disturbance (SD) NRS up to Week 184 [ Time Frame: Up to Week 184 ]
    Percentage of participants with an improvement of >=4 from baseline in Sleep Disturbance (SD) NRS up to Week 184 will be reported. SD NRS has a scale of 0 to 10, with 0 being "no sleep loss related to the symptoms of my skin disease (prurigo nodularis)" and 10 being "I did not sleep at all due to the symptoms of my skin disease (prurigo nodularis)".

  15. Percent Change from Baseline in SD NRS up to Week 184 [ Time Frame: Up to Week 184 ]
    Percent change from baseline in SD NRS up to Week 184 will be reported. SD NRS has a scale of 0 to 10, with 0 being "no sleep loss related to the symptoms of my skin disease (prurigo nodularis)" and 10 being "I did not sleep at all due to the symptoms of my skin disease (prurigo nodularis)".

  16. Absolute Change from Baseline in SD NRS up to Week 184 [ Time Frame: Up to Week 184 ]
    Absolute change from baseline in SD NRS up to Week 184 will be reported. SD NRS has a scale of 0 to 10, with 0 being "no sleep loss related to the symptoms of my skin disease (prurigo nodularis)" and 10 being "I did not sleep at all due to the symptoms of my skin disease (prurigo nodularis)".

  17. Change from Baseline in Prurigo Nodularis (PN)-associated Pain Frequency up to Week 184 [ Time Frame: Baseline up to Week 184 ]
    Change from baseline in PN-associated pain frequency up to Week 184 will be reported. The pain frequency will be assessed on a scale of 0 to 5 where 0 = never, 1 = less than once a week, 2 = 1-2 days a week, 3 = 3-4 days a week, and 4 = 5-6 days a week.

  18. Change from Baseline in PN-associated Pain Intensity up to Week 184 [ Time Frame: Baseline up to Week 184 ]
    Change from baseline in PN-associated pain intensity up to Week 184 will be reported. The pain intensity will be assessed on a scale of 0 to 10, with 0 being "no pain" and 10 being "the worst unbearable pain".

  19. Percentage of Participants Reporting low Disease Activity Based on Patient Global Assessment of Disease (PGAD) up to Week 52 [ Time Frame: Up to Week 52 ]
    Percentage of participants reporting low disease activity (clear, almost clear, or mild) based on Patient Global Assessment of Disease (PGAD) up to Week 52 to be reported.

  20. Percentage of Participants Satisfied with Study Treatment Based on Patient Global Assessment of Treatment (PGAT) up to Week 52 [ Time Frame: Up to Week 52 ]
    Percentage of participants satisfied with study treatment (good, very good, or excellent) based on Patient Global Assessment of Treatment (PGAT) up to Week 52 will be reported.

  21. Percentage of Participants with a Change of >=4 from Baseline in Dermatology Life Quality Index (DLQI) up to Week 184 [ Time Frame: Baseline up to Week 184 ]
    Percentage of participants with a change of >=4 from baseline in Dermatology Life Quality Index (DLQI) up to Week 184 will be reported. The DLQI is a validated 10-item questionnaire covering domains including symptoms/feelings, daily activities, leisure, work/school, personal relationships, and treatment. The participant will rate each question ranging from 0 (not at all) to 3 (very much). A higher total score indicates a poorer quality of life (QoL).

  22. Change from Baseline in EuroQoL 5-Dimension (EQ-5D) up to Week 184 [ Time Frame: Baseline up to Week 184 ]
    Change from baseline in EuroQoL 5-Dimension (EQ-5D) up to Week 184 will be reported. The EQ-5D instrument is a validated questionnaire, completed by the participant that consists of 2 parts. The first part consists of 5 multiple choice QoL questions and the second is a 100 point Visual Analog Scale (VAS) with 0 being "Worst imaginable health state" and 100 being "Best imaginable health state".

  23. Time to Permanent Study Drug Discontinuation [ Time Frame: Baseline to 184 weeks ]
  24. Time to Rescue Therapy [ Time Frame: Baseline to 184 weeks ]
  25. Percentage of Participants Receiving Any Rescue Treatment by Rescue Treatment [ Time Frame: Baseline up to 184 weeks ]

Eligibility Criteria
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Participants who may benefit from study participation in the opinion of the investigator and participated in a prior nemolizumab study for PN including: (a). Participants who completed the treatment period in a phase 3 pivotal study (NCT04501666 or NCT04501679) and enroll within 56 days OR (b).Participants who were previously randomized in the nemolizumab phase 2a PN study (NCT03181503)
  • Female participants of childbearing potential (that is, fertile, following menarche and until becoming post-menopausal unless permanently sterile) must agree either to be strictly abstinent throughout the study and for 12 weeks after the last study drug injection, or to use an adequate and approved method of contraception throughout the study and for 12 weeks after the last study drug injection
  • Participant willing and able to comply with all of the time commitments and procedural requirements of the clinical study protocol, including periodic weekly recordings by the participant using an electronic handheld device provided for this study
  • Understand and sign an informed consent form (ICF) before any investigational procedure(s) are performed

Exclusion Criteria:

  • Participants who, during their participation in a prior nemolizumab study, experienced an adverse event (AE) which in the opinion of the investigator could indicate that continued treatment with nemolizumab may present an unreasonable risk for the participant
  • Body weight < 30 kg
  • Pregnant women (positive pregnancy test result at screening or baseline visit), breastfeeding women, or women planning a pregnancy during the clinical study
  • Any medical or psychological condition that may put the participant at significant risk according to the investigator's judgment, if he/she participates in the clinical study, or may interfere with study assessments (example, poor venous access or needle-phobia)
  • Planning or expected to have a major surgical procedure during the clinical study
  • Participants unwilling to refrain from using prohibited medications during the clinical study
  • History of alcohol or substance abuse within 6 months prior to the screening visit
Contacts and Locations
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04204616


Locations
Show Show 164 study locations
Sponsors and Collaborators
Galderma R&D
More Information
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Layout table for additonal information
Responsible Party: Galderma R&D
ClinicalTrials.gov Identifier: NCT04204616    
Other Study ID Numbers: RD.06.SPR.202699
2019-004294-13 ( EudraCT Number )
First Posted: December 19, 2019    Key Record Dates
Last Update Posted: October 11, 2023
Last Verified: September 2023

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Prurigo
Neurodermatitis
Skin Diseases
Dermatitis
Skin Diseases, Eczematous